arsenic trioxide has been researched along with Peritoneal Carcinomatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, K; Kang, CS; Kim, M; Kim, Y; Lee, EJ; Lim, J; Moon, Y; Pai, SH; Park, G | 1 |
| Wang, B; Zhang, J | 1 |
2 other study(ies) available for arsenic trioxide and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cell Survival; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxides; Peritoneal Neoplasms; Xenograft Model Antitumor Assays | 2004 |
Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Ovarian Neoplasms; Oxides; Peritoneal Neoplasms; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2006 |